Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 7/20 | 0.44 |
| ▸ | HRH1 | P35367 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932251 | 0.90 | POLB (0.46) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL9405372 | 0.88 | POLB (0.73) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL4698574 | 0.87 | POLB (0.56) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL1991233 | 0.86 | POLB (0.55) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL4933010 | 0.84 | ALDH1A1 (0.56) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL953403 | 0.83 | SMN1; SMN2 (0.59) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL15932265 | 0.81 | ALDH1A1 (0.39) | POLBSMN1; SMN2LMNAALDH1A1HTT | |
| SCHEMBL5594520 | 0.81 | POLB (0.65) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL14590615 | 0.81 | POLB (0.65) | POLBSMN1; SMN2LMNAHRH2HRH1 | |
| SCHEMBL5594524 | 0.81 | POLB (0.65) | POLBSMN1; SMN2LMNAHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | POLB 3945/4885SMN1; SMN2 4885/4885LMNA 4677/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | POLB 3945/4885SMN1; SMN2 4885/4885LMNA 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.